Primary Outcome
Benralizumab improved both the endoscopic nasal polyp score and
corresponding CT score (LMS) by week 20 (SD=1.03; P=0.004, and SD=4.31;
P=0.012 respectively) compared to baseline. The change in polyp score
and CT score compared to placebo was -0.5 and -2.6 respectively, however
this did not reach statistical significance. Eight out of twelve
benralizumab treated subjects (66%) improved by endoscopy and nine of
twelve (75%) improved by CT scan. The mean change in endoscopic polyp
score was -0.9 with treated subjects improving from 0 to -3 points. No
subject worsened in the benralizumab treatment group.
There was no significant change from baseline in NP score (P=0.166) or
CT score (P=0.233) among placebo treated subjects at week 20. As shown
in Figure 2, there was a modest and non-significant improvement in mean
NP score among the placebo group of -0.3, a change that was 3-fold less
than the benralizumab treated group.